Literature DB >> 31331494

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Ignace Vergote1, Robert L Coleman2, Sandro Pignata3, Michael A Bookman4, Christian Marth5, Thomas J Herzog6, Antonio Gonzalez-Martin7, Larry J Copeland8.   

Abstract

Keywords:  ENGOT; GOG-Foundation; Industry clinical trials; Lead study group; Requirements

Mesh：

Year:  2019        PMID： 31331494     DOI： 10.1016/j.ygyno.2019.04.677

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  1 in total

1.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Authors:  Kathleen N Moore; Michael Bookman; Jalid Sehouli; Austin Miller; Charles Anderson; Giovanni Scambia; Tashanna Myers; Cagatay Taskiran; Katina Robison; Johanna Mäenpää; Lyndsay Willmott; Nicoletta Colombo; Jessica Thomes-Pepin; Michalis Liontos; Michael A Gold; Yolanda Garcia; Sudarshan K Sharma; Christopher J Darus; Carol Aghajanian; Aikou Okamoto; Xiaohua Wu; Rustem Safin; Fan Wu; Luciana Molinero; Vidya Maiya; Victor K Khor; Yvonne G Lin; Sandro Pignata
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.